An Illinois mistrial involving the recalled medication Zantac is the latest court decision involving the recalled drug, but ...

GSK has won its latest trial over whether its former best-selling ... known as NDMA that had been found in GSK’s heartburn ...

Delaware’s top court ruled in GSK’s favor in saying it will review the admissibility of expert evidence in an upcoming trial ...

UK-based GlaxoSmithKline PLC (GB:GSK) has won the latest U.S. trial concerning its heartburn drug Zantac (ranitidine), amid litigation over alleged cancer risks. The Florida State Court ruled in ...

Twelve days after GSK secured a key win in Florida ... to take to early trials. On the first track, plaintiffs have retained 10 experts to offer their opinions on whether ranitidine can cause ...

Kimbrow, 73, said he took Zantac from 1995 to 2019. There have been tens of thousands of lawsuits since 2020 and there are no doubt many more in the pipeline but few have gone to trial ... refile the ...

A Chicago jury failed to reach a verdict Sept. 18 over claims that heartburn drug Zantac causes cancer, Reuters exclusively reported.

GSK plc (LSE/NYSE: GSK), a leading global pharmaceutical company, has reached a confidential settlement in a Zantac (ranitidine ... SWIFT-2 phase III clinical trials. However, the company ...

Plaintiffs in the case have argued that ranitidine can cause cancer. The drug was marketed for years by GSK (GSK) under the brand name Zantac and by various generic drugmakers. GSK (GSK ...

(Reuters) - GSK won the latest trial over claims that discontinued heartburn drug Zantac caused cancer, as a jury on Monday found that the drug was not responsible for an Illinois woman's illness ...

Zamboni is expected to say the 'Tanner study - which was not submitted to the FDA until 2019 - provides evidence that GSK knew about Zantac's potential health impacts, but failed to make the ...

GSK plc (LSE/NYSE: LON:GSK), a leading global pharmaceutical company, has reached a confidential settlement in a Zantac (ranitidine ... in its SWIFT-1 and SWIFT-2 phase III clinical trials. However, ...